-
Real-world study (RWS) gained prominence starting with a significant investigation on ramipril’s impact on hypertension in 1993 (1). A key advancement for the Food and Drug Administration (FDA) occurred with the enactment of the 21st Century Cures Act in 2016, emphasizing RWS (2). The FDA’s Real-world Evidence Program establishes real-world data (RWD) as “data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources”, while real-world evidence (RWE) is “clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD” (3). The proliferation of big data, electronic medical records (EMR), electronic health records (EHR), and medical claims data offers vast information resources facilitating RWS. Enhanced access to RWD allows for worldwide monitoring of the impacts of various public health initiatives like vaccination programs. While randomized clinical trials (RCTs) traditionally gauge vaccine efficacy and short-term safety, RWS can assess vaccine performance and safety across larger, more diverse populations and are adept at identifying rare events not easily discernible in RCTs due to their infrequency.
The FDA established definitions for RWD and RWE in 2018, yet there is a lack of globally standardized definitions for RWD and RWE (4). Given the array of vaccine-preventable conditions and the variety of implementation methods, real-world studies (RWS) on vaccine use draw from a broad range of data sources and employ numerous study designs. Although previous systematic reviews have concentrated on assessing the real-world effectiveness and safety of individual vaccines, some investigations meet the requirements for RWD but do not explicitly incorporate RWD or RWE concepts. Furthermore, there is an absence of an established, overarching definition for RWS, as well as a standardized framework for evaluating vaccines. Consequently, the aims of this study were to: 1) examine the trends and applications of RWS in vaccine evaluation, and 2) describe the study designs and data sources used in RWS concerning vaccine evaluation.
-
We utilized the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines to conduct our scoping review (5), following this method to obtain thorough and relevant results.
-
We conducted a literature search on PubMed, Web of Science, CNKI, and Wanfang Database from December 2016 to July 2023. The search included studies in English or Chinese using the keywords “real-world study”, “real-world research”, “real-world data”, “real-world evidence”, “vaccine”, and “vaccination”.
-
The study encompassed human vaccination research on effectiveness, safety, immunogenicity, impact, health economics, vaccination coverage rates (VCR), vaccine hesitancy, and related factors. Excluded were non-human studies, research on methodology, databases, medicine, and treatment, as well as case reports, reviews, perspectives, letters, news articles, and comments.
-
Two researchers (WL and YH) reviewed titles, abstracts, and full texts of the articles. Discrepancies were resolved by consulting with the principal investigator (WH). Data were gathered utilizing a standardized Excel sheet, then summarized based on publication date, country, authorship, vaccine type, study purpose, design, population demographics, sample size, and data origin. Findings were delineated and juxtaposed by vaccine types, study methodologies, and data resources.
-
The initial search found 792 articles, with 243 duplicates removed. After excluding 271 articles based on title and abstract review, 278 articles underwent full-text screening. Additionally, 12 articles were identified through reference list review and manual search. Ultimately, 154 articles were included in the synthesis (Figure 1).
Figure 1.Flowchart illustrating the process of identification, selection, eligibility, and inclusion of studies for analysis.
Abbreviation: CNKI=China National Knowledge Infrastructure.
Note: Wrong publication type: reviews, perspectives, letters to the editor, news articles, and comments. Irrelevant studies: studies on animals, databases, medicine, and treatment.
-
The figure in Figure 2A illustrates the publication trend of studies that mentioned keywords related to RWD/RWE/RWS from December 2016 to July 2023. The number of publications notably increased annually, peaking at 75 studies in 2022. Among the 154 articles, 111 were from high-income countries or regions, according to the World Bank Development Indicators (https://www.worldbank.org). The most researched vaccine, with 111 studies, was the coronavirus disease 2019 (COVID-19) vaccine, followed by the HPV vaccine, the influenza vaccine, and the pneumonia vaccine, each with 9 studies (Figure 2B). Figure 2C shows that the studies covered 34 countries, with China leading in the number of vaccine-related real-world studies (33 studies), followed by the United States (28 studies). The primary uses of real-world studies were to assess effectiveness (81 studies), safety (40 studies), and immunogenicity (22 studies). Additionally, two studies on the EV71 vaccine were exclusively conducted in China. Real-world studies were also applied to evaluate vaccine coverage rates, health economics, impact, vaccine hesitancy, willingness to pay, and awareness of vaccine evaluations.
-
The most common study designs in the literature reviewed were cohort studies (86 studies) and case-control studies (28 studies). Cohort studies were predominantly utilized for assessing effectiveness (45 studies) than safety (15 studies) or immunogenicity (15 studies), while case-control studies, particularly the test-negative design (16 out of 26 studies), were commonly employed for evaluating vaccine effectiveness. Cross-sectional studies were frequently utilized for assessing vaccine safety (21 studies). Additionally, other study designs such as target trial emulation studies, screening methods, ecological studies, and pragmatic randomized clinical trial (PCT) were employed for vaccine effectiveness evaluation. Furthermore, two studies utilized modeling for economic evaluations of vaccines (Table 1).
Categories Effectiveness Safety Immunogenicity Impact Economics VCR Hesitancy Other* Total Study design 161† Cohort 45 15 15 3 3 5 86 Case-control 26 2 28 Cross-sectional 21 7 1 2 2 33 Target trial emulation 4 1 5 Screening method 2 2 Ecological 2 1 3 Model 2 2 PCT 1 1 CRCT 1 1 Data source 163† Administrative database 49 20 2 3 3 2 79 EMR/EHR 11 4 1 1 17 Claims database 4 1 3 8 Registry 5 5 Survey 13 16 20 1 2 2 54 Abbreviation: VCR=vaccination coverage rates; PCT=pragmatic randomized clinical trial; CRCT=cluster randomized controlled trial; EMR/EHR=electronic medical records/electronic health records.
* Other: Willingness to pay, Awareness of vaccine.
† Certain study designs or data sources involve multiple applications.Table 1. Characteristics of real-world studies on vaccines.
-
Table 1 demonstrates that administrative databases were predominantly utilized in 49 studies for assessing vaccine effectiveness in real-world scenarios. For evaluating immunogenicity, survey data from real-world settings were commonly employed in 20 studies. In terms of vaccine safety assessment, researchers frequently examined large-scale datasets from administrative databases (20 studies) and survey databases using RWD tailored for specific research goals (16 studies). Most parameters for economic evaluations of vaccines were sourced from administrative databases, medical claims databases with cost records, and electronic medical records. Among the reviewed studies, only three used administrative databases for the economic assessment of vaccines. In the evaluation of HPV vaccine effectiveness in real-world studies, registry databases were the primary information source for HPV diseases in 4 out of 9 studies. Utilization of claims databases in real-world vaccine evaluations was infrequent, constituting only 4.9% of the total, whereas EMR/EHR accounted for 10.4%.
HTML
METHODOLOGIC FRAMEWORK
Search Strategy
Selection Criteria
Data Extraction and Synthesis
Literature Screening
Trends and Applications of Real-World Study in Vaccine Evaluation
Study Designs of Real-World Study in Vaccine Evaluation
Data Sources of Real-World Study in Vaccine Evaluation
Citation: |